August 16, 2023
For evolving advanced therapy products with very short timelines between manufacturing and delivery to patients, efficient biosafety testing is crucial as failure to detect the presence of adventitious agents early can have devastating consequences. Next-Generation Sequencing (NGS) technology provides an untargeted, accurate, and rapid method for identifying all biological contamination and is suitable for testing starting materials, unprocessed bulk harvest, and the final product. A major challenge of using NGS for biosafety testing and quality control is achieving fast, efficient and reproducible analysis of the large volume of data it produces.
Genedata Selector® is an end-to-end software solution that enables biopharmaceutical organizations to perform product safety, quality, and integrity testing in-house.